

CAPRELSA (vandetanib)

## **Pre - PA Allowance**

None

# **Prior-Approval Requirements**

Age 18 years of age or older

## Diagnoses

Patient must have the following:

- 1. Symptomatic or progressive medullary thyroid cancer
- 2. Unresectable locally advanced disease or metastatic disease
- 3. No hypocalcemia, hypokalemia, or hypomagnesemia before the initiation of Caprelsa
- 4. No congenital long QT syndrome
- 5. Physician must complete Risk Evaluation and Mitigation Strategy (REMS) program.

# **Prior - Approval Limits**

## Quantity

Strength	Quantity
100 mg	270 tablets per 90 days OR
300 mg	90 tablets per 90 days

**Duration** 12 months

# Prior-Approval Renewal Requirements

Age 18 years of age or older

## Diagnosis

Patient must have the following:

Symptomatic or progressive medullary thyroid cancer

## **AND** the following:

1. Physician must complete Risk Evaluation and Mitigation Strategy (REMS) program.



CAPRELSA (vandetanib)

# Prior-Approval Renewal Limits

Same as above